4 weeks HC Wainwright Has Lowered Expectations for Summit Therapeutics (NASDAQ:SMMT) Stock PriceMarketBeat
HC Wainwright lowered their price objective on Summit Therapeutics from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday.
X